Suominen, M.I.; Mäki-Jouppila, J.; Huhtinen, A.; Sjöholm, B.; Rissanen, J.P.; Luostarinen, A.; Fagerlund, K.M.; Alhoniemi, E.; Siemeister, G.; Mumberg, D.;
et al. Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model. Int. J. Mol. Sci. 2021, 22, 5570.
https://doi.org/10.3390/ijms22115570
AMA Style
Suominen MI, Mäki-Jouppila J, Huhtinen A, Sjöholm B, Rissanen JP, Luostarinen A, Fagerlund KM, Alhoniemi E, Siemeister G, Mumberg D,
et al. Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model. International Journal of Molecular Sciences. 2021; 22(11):5570.
https://doi.org/10.3390/ijms22115570
Chicago/Turabian Style
Suominen, Mari I., Jenni Mäki-Jouppila, Anna Huhtinen, Birgitta Sjöholm, Jukka P. Rissanen, Anniina Luostarinen, Katja M. Fagerlund, Esa Alhoniemi, Gerhard Siemeister, Dominik Mumberg,
and et al. 2021. "Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model" International Journal of Molecular Sciences 22, no. 11: 5570.
https://doi.org/10.3390/ijms22115570
APA Style
Suominen, M. I., Mäki-Jouppila, J., Huhtinen, A., Sjöholm, B., Rissanen, J. P., Luostarinen, A., Fagerlund, K. M., Alhoniemi, E., Siemeister, G., Mumberg, D., Käkönen, S. -M., & Scholz, A.
(2021). Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model. International Journal of Molecular Sciences, 22(11), 5570.
https://doi.org/10.3390/ijms22115570